OKUR
OnKure Therapeutics, Inc.
Key Financials
Operating Income
$-62950000
↓ 15.7%
Revenue
$0
N/A
Net Income
$-59517000
↓ 13.0%
Total Assets
$62.1M
↓ 45.9%
Shareholders' Equity
$56.2M
↓ 45.9%
Cash & Equivalents
$59.0M
↓ 46.7%
Total Liabilities
$5.9M
↓ 46.4%
EPS (Diluted)
$-4.40
↑ 71.2%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 3 | 4/7/2026 | View on SEC |
| SCHEDULE 13D | 4/7/2026 | View on SEC |
| SCHEDULE 13G | 4/7/2026 | View on SEC |
| SCHEDULE 13G | 4/7/2026 | View on SEC |
| SCHEDULE 13G | 4/7/2026 | View on SEC |
| 4 | 4/3/2026 | View on SEC |
| 4 | 4/3/2026 | View on SEC |
| 4 | 4/3/2026 | View on SEC |
| 4 | 4/3/2026 | View on SEC |
| 4 | 4/1/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | OKUR |
| Company Name | OnKure Therapeutics, Inc. |
| CIK | 1637715 |
| Sector | Pharmaceutical Preparations |
| Industry | Emerging growth company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | (720) 307-2892 |